《爱尔兰时报》10月14日报道，在美国总统向17家大型制药集团发出警告信后，从辉瑞、礼来到罗 氏、赛诺菲和阿斯利康等制药巨头都在排队与特朗普合作，其中许多公司希望避免可能出现的惩罚性关 税。阿斯利康上周末同意以低于美国政府医疗补助计划的折扣价出售部分药品，以换取三年的关税减 免。这项"最惠国"协议与辉瑞公司上个月底达成的一项协议如出一辙，辉瑞公司同意将医疗补助计划中 的处方药价格降低至其他发达国家的水平，以换取关税减免。两家公司达成的协议以及在包括英国在内 的其他地方提高价格的举措，现在已成为所有大型制药集团在未来几周和几个月内预计要遵循的模板。 目前，艾伯维、百时美施贵宝和赛诺菲都在降低药品价格，礼来、罗氏和诺和诺德希望绕过中间商，直 接向客户销售。美国处方药价格遥遥领先，通常比其他发达市场高出近三倍。特朗普凭借其霸凌策略， 成功地以一种前所未有的方式迫使大型制药公司屈服。 （原标题：大型制药公司屈服于特朗普压力） ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 艾滋病 （AIDS） ，全称为 获得性免疫缺陷综合征 ，是由 人类免疫缺陷病毒 （HIV） 感染所引起的免疫系统进行性衰竭的疾病阶段。据统计，目前全世界有约 有 4000 万人感染了 HIV 病毒，这导致艾滋病成为全球公共卫生的重要威胁。 抗逆转录病毒疗法 （ART） 是通过 联合使用多种抗逆转录病毒药物来抑制 HIV 病毒复制的标准治疗方案，能够将 HIV 病毒载量抑制在低水平，从而有效降低传 播风险以及疾病进展和死亡风险。 然而，ART 并不能治愈患者，持续的低水平炎症依然存在，合并症风险以及长期治疗相关的毒副作用也依然存在，此外，ART 疗法需要每天服药，这对用药依从 性来说颇具挑战性。如果能够实现 一次给药，长期持续抑制 HIV 病毒 ，将从 根本上改变当前的 HIV 治疗模式， 并显著改善感染者的的生活。 BudigalimabBudigalimab (ABBV 181; PR 1648817) 是一种靶向程序性细胞死亡蛋白 1 (PD-1)的人源化单克隆抗体，具有Fc突变，可减少Fc受体相互作用和效 应因子抑制作用 2025 年 10 月 15 日，加拿大麦 ...

Group 1 - The article discusses AbbVie (NYSE: ABBV) and its recent FDA approvals for Skyrizi and Rinvoq, which are expected to positively impact the company's performance following the patent loss of Humira [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] Group 2 - The article does not provide specific financial data or performance metrics related to AbbVie or the pharmaceutical industry [1][3][4]

Core Points - Opawica Explorations Inc. has granted a total of 900,000 stock options to certain directors and officers as part of its stock option plan [1][2] - Each option allows the acquisition of one common share at a price of $0.09 per share for a period of three years from the date of grant [2] - The options are subject to a four-month hold period from the date of issuance in accordance with applicable securities laws [2] Company Overview - Opawica Explorations is a Canadian resource exploration company focused on precious and base metal properties in the Rouyn-Noranda region of the Abitibi gold belt in Quebec [4] - The management team has a strong track record in discovering and developing successful exploration projects [4] - The company's objective is to enhance shareholder value through cost-effective exploration practices, acquiring additional properties, and seeking partnerships with industry leaders [4] Property Details - Opawica's Bazooka properties span seven kilometers of the CLLB and are adjacent to the Wassamac gold property, which is fully owned by Richmont Mines Inc. [5]

Accessibility StatementSkip Navigation Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORTH CHICAGO, Ill., Oct. 17, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist an ...

AbbVie (NYSE:ABBV) snapped six consecutive sessions of losses on Thursday as the stock ended 0.29% lower at $226.87. Since October 8, the stock has closed in the red every day until October 15, during which ABBV lost over 2%. On a year-to-date basis, it ...

AbbVie Inc. (NYSE:ABBV) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV) Photo by Dan Dennis on Unsplash A global pharmaceutical company, AbbVie Inc. (NYSE:ABBV) is among the best dividend stocks in the healthcare sector. On October 14, C‍antor Fitzgerald reaffirmed⁠ its Overwe⁠ight rating a⁠nd $2‍5⁠0 price targ⁠et‌ f‍or AbbVie Inc. (NYSE:ABBV) while revising its earnings model⁠ to inclu⁠de the‍ tax effects⁠ of a pl ...

AbbVie (ABBV) closed the most recent trading day at $226.22, moving -1.27% from the previous trading session. This move lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.66%. Shares of the drugmaker have appreciated by 5.95% over the course of the past month, outperforming the Medical sector's gain of 1.8%, and the S&P 500's gain of 1.02%.The upcoming earnings release of AbbVie will be of great interest to investors. The company's earnings report is ...

Key Points Dividend growth tends to mirror earnings growth better than static ratios. Rising payouts usually signal durable cash flow, pricing power, and disciplined capital allocation, effectively functioning as an underappreciated valuation cue. These three dividend payers are proven businesses with a long record of rewarding shareholders. 10 stocks we like better than Costco Wholesale › Dividend growth is a reliable edge. Over long periods, companies that regularly raise their dividends have of ...

Key Takeaways Skyrizi and Rinvoq momentum has restored AbbVie's top-line growth after Humira's U.S. patent loss.Strong demand in IBD and new indications like UC and GCA are expected to lift Q3 performance.ABBV is diversifying with rising sales in neuroscience and oncology, driven by newer therapies.AbbVie (ABBV) remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq. The robust demand for both drugs has helped the company retu ...